Clinical Trials Browser

Phase 1 × Immunoconjugates × Breast × Clear all

NCT03255070 2024-02-01

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

Phase 1 Completed

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms